EHA Unplugged European Hematology Association

Join us for a discussion with Prof Paolo Ghia, MD, PhD, from Università Vita Salute San Raffaele, Milan (Italy), as he explores how precision medicine is transforming CLL treatment. 
In this episode, discover how precision medicine is used daily in CLL to decide the best management and  treatment for patients. Listen to Prof Ghia explain how CLL management is moving from traditional chemotherapy to targeted therapies based on specific genetic markers, like immunoglobulin mutational status or P53 aberrations, which help guide treatment decisions. 

Explore the array of targeted therapies available for CLL, including BTK inhibitors and BCL-2 inhibitors, and understand how they target critical pathways in CLL pathogenesis. Gain insights from Prof Ghia on the complexities of selecting the right therapy for each patient based on genetic profile, disease risk, and individual preferences. 
 
Through the discussion, recognise the challenges in CLL management, such as relapse scenarios and emerging therapies, and learn the research strategies being explored for potential cures in CLL
 
This is a series of podcasts covering precision medicine across several disorders, more podcasts will be available in the future. Stay tuned! 

Host: Isabel Olivera-Martinez, PhD
Guest: Prof Lucia de Franceschi

This is the eighth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn More
Interested in more content related to CLL? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us on this podcast episode featuring Prof Lucia de Franceschi (Department of Medicine, University of Verona, Italy) as she discusses the latest advances on the use of Pyruvate kinase activators in the treatment of rare hematological diseases. 
 
Learn about the crucial role of Pyruvate kinase (PK) in erythrocyte metabolism and how pyruvate kinase activators are emerging as a new therapeutic option for chronic hemolytic anemias  that had previously no other treatment than transfusion or iron chelation. 
Discover how two oral pyruvate kinase activators, Mitapivat and Etavopivat, can help improve ineffective erythropoiesis and survival of  red cells and therefore are being tested as a new therapeutic scenario for non-transfusion dependent thalassemia patients and sickle cell disease patients. 

Discover how PK activators are able to reprogram red cells to a more normal metabolite context, which can have a beneficial effect in a wide range of rare diseases all characterized by an abnormal metabolite profile, which represents the ideal breakthrough in the management of rare diseases, as one drug has the ability to treat multiple disorders.
 
This is a series of podcasts covering precision medicine across several disorders, more podcasts will be available in the future. Stay tuned! 

Host: Isabel Olivera-Martinez, PhD
Guest: Prof Lucia de Franceschi

This is the seventh episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn More
Matte, Alessandro, Enrica Federti, and Lucia De Franceschi. 2023. ‘Erythrocyte Pyruvate Kinase Activation in Red Cell Disorders’. Current Opinion in Hematology 30 (3): 93. https://doi.org/10.1097/MOH.0000000000000758.

Interested in more content related to Thalassemia? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via a href="https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer"...

Join us for this captivating interview with our guest Prof Stefano Luminari, MD, PhD, from the University of Modena and Reggio Emilia in Italy, as he explores what precision medicine means today for follicular lymphoma. 
Together with our host Dr. Isabel Olivera-Martinez, they discuss the current precision medicine approaches to the diagnosis and treatment of follicular lymphoma. They explore the molecular events underlying the disease, the latest targeted therapies, and the future of treatment for follicular lymphoma. Professor Luminari shares his insights on the most promising developments in the field, including T cell engagers, bispecific antibodies, and CAR-T therapies. He also discusses the importance of considering not only the efficacy of these treatments but also their impact on the quality of life and long-term outcomes for patients. This episode provides a comprehensive and enlightening discussion on the current state and future of follicular lymphoma treatment.  
 
This is a series of podcasts covering precision medicine across several disorders, more podcasts will be available in the future. Stay tuned! 
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Stefano Luminari
This is the sixth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for a captivating discussion with Prof Pieter Sonneveld, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, the Netherlands, as he explores the evolution of precision medicine in multiple myeloma. 
Prof. Sonneveld outlines the improvements in multiple myeloma treatment over the past decade, describing the progressive addition of targeted therapies such as daratumumab and bispecific antibodies, BiTEs, and CAR-T cells to the therapeutic arsenal. 
Discover how treatment selection now hinges on whether a one-off or continuous therapy is most suitable, acknowledging the challenges of limited availability in Europe due to cost considerations. Learn about the outstanding findings from the phase III PERSEUS trial, demonstrating the effectiveness of daratumumab combined with lenalidomide for newly diagnosed transplant-eligible patients and transforming their standard of care. 
This interview unveils cutting-edge strategies that are reshaping myeloma prognosis and underscores the importance of early adoption of novel therapies for improved patient outcomes.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Peter Sonneveld
This is the fifth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn More
If you'd like to learn more about Multiple Myeloma, check out the comprehensive EHA - Multiple Myeloma Program  on EHA Campus.

Interested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Welcome to this podcast episode featuring Prof Claire Harrison (Clinical Director at Guy’s and St Thomas’ NHS Foundation Trust) and Prof Jean-Jacques Kiladjian (Professor at Université Paris-Diderot and Hôpital Saint-Louis). 
 
Join them as they navigate the challenges and opportunities of precision medicine in MPNs, discover how advancements in molecular techniques are reshaping disease diagnosis, patient stratification and treatment tailoring.  
 
Gain insights into the evolving landscape of targeted therapies for MPNs, including JAK inhibitors and emerging strategies for CALR mutation targeting. 
 
Listen as our experts highlight the heterogeneity of clinical needs based on individual patients' molecular profiles and the promise of personalised treatment approaches bringing exciting prospects for improving patient outcomes in this dynamic field. 
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Claire Harrison and Prof Jean-Jacques Kiladjian
This is the fourth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!

Learn More
If you'd like to learn more about MPN, check out the EHA - Myeloproliferative Neoplasms Program  on EHA Campus.

Interested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us on this podcast episode featuring Prof Helen Papadaki (University of Crete, Greece) as she discusses the link between clonal hematopoiesis and the risk of developing MDS or AML. 
 
Prof. Papadaki begins by explaining the difference between CHIP (clonal hematopoiesis of indeterminate potential), CCUS (clonal cytopenia of undetermined significance) and ICUS (Idiopathic cytopenia of undetermined significance). She underlines the clinical relevance of the association of clonal hematopoiesis with cytopenias, as a clear indicator of an increased risk of developing hematological malignancies. 
 
Learn how important it is to better characterize by NGS sequencing the specific mutations of the clones, given that the type of mutation, the number of mutations, and the combination of mutations are critical parameters in accurately predicting the risk of developing MDS or AML. 
 
Furthermore, Prof Papadaki explains the importance of discriminating between acquired and germline mutations leading to clonal hematopoiesis and their relationship with age. Finally, she highlights the fact that clonal hematopoiesis is a risk factor for developing not only hematological malignancies but also cardiac diseases. 
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Helen Papadaki

This is the third episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!

Learn More  
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe